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Background: The association between family history and risk of triple negative breast cancer and ductal carcinoma
in situ (DCIS) has not been well investigated, especially in Asian populations. We investigated the association
between family history and risk of DCIS or triple negative breast cancer in a Han Chinese population.
Methods: A case–control study, comprising 926 breast cancer patients and 1,187 benign breast disease controls,
was conducted in our hospital. Multivariate logistic regression was used to assess the relationships between family
history and risk of DCIS or triple negative breast cancer.
Results: Subjects with a family history of breast cancer had higher breast cancer risk than those without a family history
(odds ratio (OR) = 2.11, 95% confidence interval (CI) = 1.26 to 3.52). Family history was not significantly associated with
an increased risk of DCIS (OR = 1.27, 95% CI = 0.36 to 4.46), while family history was significantly associated with an
increased risk of invasive breast cancer (OR = 2.22, 95% CI = 1.32 to 3.75), irrespective of triple negative breast cancer
(OR = 3.35, 95% CI = 1.43 to 7.88) or non-triple negative breast cancer (OR = 2.14, 95% CI = 1.21 to 3.80).
Conclusion: Our results indicate that having a family history of breast cancer is associated with an increased risk of triple
negative breast cancer with a magnitude of association similar to that for non-triple negative breast cancer. Furthermore,
family history is not significantly associated with an increased risk of DCIS. Future cohort studies with larger sample sizes
are still needed to explore these relationships.
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Breast cancer is a worldwide malignant disease, and it is
the leading cause of cancer-related death in women
[1,2]. There is plentiful evidence to indicate that breast
cancer is an epidemiologically, biologically, and clinically
heterogeneous disease [3]. A special subgroup of pa-
tients is associated with aggressive clinical behavior and
poor outcome [4-6]. This subgroup of breast cancer is
characterized by absent expression of estrogen receptor
(ER), progesterone receptor (PR) and HER2 receptor
and is defined as triple negative breast cancer.* Correspondence: ws0801@hotmail.com
†Equal contributors
1Department of Breast Surgery, The First Affiliated Hospital with Nanjing
Medical University, 300 Guangzhou Road, Nanjing 210029, China
Full list of author information is available at the end of the article
© 2013 Zhou et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orTo the authors’ knowledge, few risk factors for this
breast cancer subtype have been identified. Family history
is a key risk factor of breast cancer [7-12]. However, the
association between family history and risk of triple nega-
tive breast cancer has not been well investigated. Some
studies suggest that there is no difference in the preva-
lence of family history between women with triple nega-
tive breast cancer (or basal-like breast cancer) and other
types of breast cancer [3,13]. By contrast, another previous
study [14] suggests that a family history was associated
with an increased risk of basal-like breast cancer. Further-
more, Jiang and colleagues observed an increased propor-
tion of ER and PR negative breast cancer among younger
Spanish women with a family history of breast cancer
[15]. Therefore, the relationship between family history
and risk of triple negative breast cancer is still not clear.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nificantly affected by racial or ethnic difference [15-19].
For example, previous studies suggested that Hispanic
women had a lower rate of breast cancer than non-Hispanic
white women, while Hispanic breast cancer patients were
more likely to die of breast cancer than non-Hispanic white
patients [15,20]. Furthermore, about 20% of Hispanic inva-
sive breast cancer patients had a family history [15], while
the proportion of breast cancer patients with a family his-
tory was only about 6.6% in a cross-sectional survey in
China [1]. Up to now, there are limited amounts of data on
the association between family history and triple negative
breast cancer risk in Asian populations. Furthermore, there
is little data on the relationship between family history and
risk of ductal carcinoma in situ (DCIS) [21-25]. However,
there is no data on the association between family history
and risk of DCIS in Asian populations.
The aim of this study was to investigate the association
between family history and risk of DCIS or triple nega-
tive breast cancer in a Han Chinese population. To our
knowledge, this case–control study represents one of the
first studies to determine these relationships in a large
population of Chinese women.
Methods
Ethics
The study was approved by the ethics committee of the
First Affiliated Hospital with Nanjing Medical Univer-
sity, and was performed in compliance with the Helsinki
Declaration. All patients provided written informed con-
sent for their clinical data to be reviewed by us.
Study population
Women with histologically confirmed breast cancers, on
whom surgeries were performed by one group of sur-
geons in the First Affiliated Hospital with Nanjing Med-
ical University from May 2005 to July 2012 were
recruited as the case group. All subjects in this study
were diagnosed with incident breast cancer, and were
recruited without restriction of age or histological type.
The patients were ethnic Han Chinese coming from dif-
ferent families. Patients with previous cancer history,
metastasized cancer from other organs, and previous
chemotherapy or radiotherapy were excluded. A control
group of subjects with histologically confirmed benign
breast disease, on whom surgeries were performed by
the same group of surgeons in the same period, was also
recruited. Both groups of patients were recruited with-
out restriction of age, and were all ethnic Han Chinese,
from different families without previous cancer history.
Data collection
The database of breast disease (breast cancer and benign
breast disease) in our hospital was reviewed. Familyhistory was defined as a history of breast cancer in any
first-degree or second-degree relative [15]. Risk factors and
clinical information were collected from medical records
by trained physicians. The following selected risk factors
were extracted if available: age at diagnosis, age at menar-
che, previous childbearing history, and family history of
breast cancer. The following clinicopathologic variables
were selected: pathology, tumor size, number of positive
lymph nodes, ER status, PR status, and HER2 status.
Pathology
For histopathological examinations, the specimens were
paraffin-embedded. Then, 4 μm histological sections were
cut and stained with H & E. Immunohistochemical ana-
lyses on paraffin-embedded material were used to deter-
mine the ER and PR status, as described previously [26].
HER2 status was determined according to the American
Society of Clinical Oncology guidelines [27]. DCIS with
microinvasion ≤1 mm was used as the DCIS category. All
patients with invasive breast cancer in this study were cate-
gorized into two subgroups: triple negative and non-triple
negative. Either or both of ER and PR positive were consid-
ered hormone receptor positive, while both ER and PR
negative were considered hormone receptor negative. Triple
negative breast cancer was defined as ER, PR, and HER2 all
negative. The pathology for both case and control groups
was reviewed independently by an experienced pathologist.
Statistical analysis
Percentiles were used to analyze for numerical variables,
and mean ± standard deviation (SD) was also used to re-
port the numerical data. Student’s t test was applied to
identify the difference of mean age between the case and
control groups. The chi-square test was applied to examine
the differences for unordered categorical variables between
the case and control groups, while the nonparametric rank
test was applied to examine the differences for ordinal cat-
egorical variables between the two groups. Multivariate lo-
gistic regression analyses were performed to identify risk
factors of breast cancer and subtype-specific breast cancer.
The candidate explanatory variables in the multivariate lo-
gistic regression analysis were: age at diagnosis, age at me-
narche, previous childbearing history, and family history of
breast cancer. Importantly, those with a family history of
breast cancer are often diagnosed much younger than
those without a family history. Age at diagnosis can there-
fore be an intermediate between family history and the
occurrence of breast cancer. Adjusting for a disease inter-
mediate can result in bias away from the null. So we also
ran these analyses without age at diagnosis to see how
much this affected the odds ratio (OR). Age at diagnosis in
this study was categorized into seven subgroups: ≤30,
31 to 40, 41 to 50, 51 to 60, 61 to 70, 71 to 80, and ≥81.
Age at menarche was categorized into three subgroups:
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in this study was categorized into four subgroups: 0, 1,
2, and ≥3. Odds ratios and 95% confidence interval (CI)
were used to assess breast cancer risk of candidate explana-
tory variables. All statistical analyses were performed using
Stata version 11.0 (StataCorp, College Station, Texas). All
tests were two-sided and a level of significance of 0.05
was applied.
Results
A total of 926 women with breast cancer and 1,187 women
with benign breast disease were studied. The selected char-
acteristics for breast cancer patients and control subjects
are presented in Table 1. The mean age of the control
group (44.8 ± 12.5) was younger than that of the case group
(52.2 ± 12.2) (P < 0.001). Age at menarche was not well bal-
anced between these two groups (P < 0.001). Furthermore,
more patients in the case group had two or more children
(30.6%) than in the control group (19.4%) (P < 0.001); this
was in accordance with the age distribution between the
two groups. In this study population, 5.1% of breast cancer
patients had a family history of breast cancer, which was
higher than that in control group (3.2%) (P = 0.012).Table 1 Distribution of selected variables between breast






N % N %
Age at diagnosis (mean ± SD), years 52.2 ± 12.2 44.8 ± 12.5 <0.001
≤50 453 48.9 819 69.0 <0.001
>50 473 51.1 368 31.0
Age at menarche, years
≤13 144 15.6 229 19.3 <0.001
14 to 16 406 43.8 643 54.2
≥17 138 14.9 114 9.6
Not available 238 25.7 201 16.9
Childbearing history
0 children 26 2.8 132 11.1 <0.001
1 child 456 49.2 707 59.6
2 children 191 20.6 162 13.6
≥3 children 93 10.0 69 5.8
Not available 160 17.3 117 9.9
Family history
Yes 47 5.1 38 3.2 0.012
No 814 87.9 1143 96.3
Not available 65 7.0 6 0.5
aStudent’s t test for age distribution between case and control groups; chi-
square test for family history distribution between case and control groups;
nonparametric rank test for other variables distribution between case and
control groups.Multivariate analysis of breast cancer risk
In multivariate logistic analyses (Table 2), age at menarche
(all P > 0.1) and previous childbearing history (all P > 0.1)
were not significantly associated with an increased or de-
creased breast cancer risk when other variables were ad-
justed. Compared with subjects younger than 30 years,
increased age was significantly associated with increased
breast cancer risk in all age subgroups (31 to 40 y: OR =
6.14, 95% CI = 2.58 to 14.64; 41 to 50 y: OR = 10.31, 95%
CI = 4.34 to 24.51; 51 to 60 y: OR = 14.46, 95% CI = 6.02
to 34.69; 61 to 70 y: OR = 16.08, 95% CI = 6.41 to 40.33;
71 to 80 y: OR = 31.12, 95% CI = 11.69 to 82.89; ≥81 y:
OR = 38.86, 95% CI = 6.30 to 239.57). When other vari-
ables were adjusted, subjects with a breast cancer family
history had a higher breast cancer risk than subjects with-
out a family history (OR = 2.11, 95% CI = 1.26 to 3.52,
P = 0.004). Similar results were obtained (OR = 2.15, 95%
CI = 1.31 to 3.53, P = 0.003) when multivariate analysis
was performed without age at diagnosis.
Comparison between triple negative and non-triple
negative breast cancer
Of 926 breast cancer patients in this study, 123 patients
were diagnosed with DCIS, and 803 were diagnosed with
invasive cancer. Of these 803 invasive cancer patients,Table 2 Multivariate logistic analysis of breast cancer-related
factors compared with benign breast disease control
Variable OR 95% CI P
Age at diagnosis, years
≤30 Reference
31 to 40 6.14 2.58 to 14.64 <0.001
41 to 50 10.31 4.34 to 24.51 <0.001
51 to 60 14.46 6.02 to 34.69 <0.001
61 to 70 16.08 6.41 to 40.33 <0.001
71 to 80 31.12 11.69 to 82.89 <0.001
≥81 38.86 6.30 to 239.57 <0.001
Age at menarche, years
≤13 Reference
14 to 16 0.83 0.63 to 1.09 0.172
≥17 1.21 0.84 to 1.74 0.309
Childbearing
0 Reference
1 1.24 0.71 to 2.16 0.448
2 1.52 0.84 to 2.76 0.170
≥3 1.47 0.75 to 2.89 0.226
Family history
No Reference
Yes 2.11 1.26 to 3.52 0.004
CI, confidence interval; OR, odds ratio.
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tients, including 129 triple negative breast cancer pa-
tients, and 577 non-triple negative breast cancer
patients. The distribution of selected variables between
triple negative and non-triple negative breast cancer pa-
tients is shown in Table 3. Age at diagnosis (P = 0.354),
age at menarche (P = 0.494), and previous childbearing
history (P = 0.934) were not significantly different be-
tween triple negative and non-triple negative patients.
Furthermore, tumor size between the two groups was
not significantly different (P = 0.792). Like our previous
study [26], triple negative breast cancer (34.88%) had less
lymph node involvement than non-triple negative breast
cancer (50.26%) (P = 0.001). Importantly, the propor-
tions of patients with a family history between the two
groups were not significantly different (P = 0.599).Table 3 Distribution of selected variables between triple neg
Variable Triple negative (n = 129)
N %
Age at diagnosis, years
≤50 61 47.29
>50 68 52.71
Age at menarche, years
≤13 22 17.05
14 to 16 57 44.19
≥17 18 13.95
Not available 32 24.81
Childbearing history
0 children 4 3.10
1 child 62 48.06
2 children 28 21.71
≥ 3 children 12 9.30
Not available 23 17.83
Tumor size
≤2 cm 48 37.21
>2 cm 66 51.16








Not available 11 8.53
aChi-square test for age at diagnosis, tumor size, lymph node involvement, and fam
cancer patients; nonparametric rank test for distribution of age at menarche and ch
cancer patients.Multivariate subgroup analysis of breast cancer risk in
relation to family history
Details of the multivariate subgroup analyses of breast
cancer risk in relation to family history are shown in
Table 4. Compared with benign breast disease control,
family history was not significantly associated with an in-
creased risk of DCIS (OR = 1.27, 95% CI = 0.36 to 4.46,
P = 0.704), while family history was significantly associated
with an increased risk of invasive breast cancer (OR =
2.22, 95% CI = 1.32 to 3.75, P = 0.003) in our study.
In 803 invasive breast cancer patients, subgroup ana-
lyses regarding to tumor size, lymph node involvement,
hormone receptor status, and molecular subtype were
performed. When breast cancers were divided into two
groups according to tumor size, family history of breast
cancer was significantly associated with an increased riskative and non-triple negative breast cancer patients






















ily history distribution between triple negative and non-triple negative breast
ildbearing between triple negative and non-triple negative breast
Table 4 Risk of subtype-specific breast cancer in relation
to family history of breast cancer compared with benign
breast disease control
Variable OR (95% CI)a Pa OR (95% CI)b Pb
Pathology
DCIS 1.27 (0.36 to 4.46) 0.704 1.30 (0.38 to 4.43) 0.679
Invasive cancer 2.22 (1.32 to 3.75) 0.003 2.26 (1.36 to 3.75) 0.002
Tumor sizec
≤2 cm 1.87 (0.92 to 3.80) 0.084 1.94 (0.97 to 3.87) 0.061
>2 cm 2.29 (1.22 to 4.29) 0.010 2.34 (1.28 to 4.30) 0.006
Lymph node involvementc
Negative 2.60 (1.42 to 4.75) 0.002 2.56 (1.43 to 4.57) 0.001
Positive 2.07 (1.05 to 4.08) 0.036 2.14 (1.10 to 4.15) 0.025
Hormone receptor statusc
Negative 3.05 (1.45 to 6.41) 0.003 2.76 (1.35 to 5.64) 0.005
Positive 2.09 (1.16 to 3.78) 0.014 2.19 (1.23 to 3.89) 0.008
Molecular subtypec
Triple negative 3.35 (1.43 to 7.88) 0.005 3.17 (1.38 to 7.28) 0.007
Non-triple negative 2.14 (1.21 to 3.80) 0.009 2.20 (1.27 to 3.82) 0.005
aAdjusted for age at diagnosis, age at menarche, and childbearing; bAdjusted
for age at menarche, and childbearing history; cDCIS not included for analysis.
CI, confidence interval; DCIS, ductal carcinoma in situ; OR, odds ratio.
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4.29, P = 0.010), and borderline significantly associated
with an increased risk of breast cancer ≤2 cm (OR =
1.87, 95% CI = 0.92 to 3.80, P = 0.084). Furthermore,
family history was significantly associated with an in-
creased risk of breast cancer with negative (OR = 2.60,
95% CI = 1.42 to 4.75, P = 0.002) and positive lymph
nodes (OR = 2.07, 95% CI = 1.05 to 4.08, P = 0.036).
When breast cancers were divided into two groups
according to hormone receptor status, family history
was associated with an increased risk of both hormone
receptor negative (OR = 3.05, 95% CI = 1.45 to 6.41,
P = 0.003) and positive breast cancer (OR = 2.09, 95%
CI = 1.16 to 3.78, P = 0.014). Importantly, having a fam-
ily history of breast cancer was associated with an in-
creased risk of triple negative breast cancer (OR = 3.35,
95% CI = 1.43 to 7.88, P = 0.005) with a magnitude of
association similar to that for non-triple negative breast
cancer (OR = 2.14, 95% CI = 1.21 to 3.80, P = 0.009).
When multivariate analyses were performed without
considering age at diagnosis, the results were similar to
those given in Table 4.
Discussion
This case–control study suggests that a family history of
breast cancer is associated with an increased breast can-
cer risk; this is consistent with prior studies [7-12]. Im-
portantly, the proportions of patients with a family
history in the triple negative and non-triple negativegroups were not significantly different in Han Chinese
people. A family history of breast cancer was associated
with an increased risk of triple negative breast cancer,
with a magnitude of association similar to that for non-
triple negative breast cancer in multivariate analyses.
Furthermore, family history was not significantly associ-
ated with an increased risk of DCIS in our study.
Consistent with previous studies [3,7-12], our data in-
dicate a 2.11-fold increased breast cancer risk in women
with any-degree family history. However, subjects with
benign breast disease, which is an important risk factor
for subsequent breast cancer [8], were applied as con-
trols. Furthermore, the proportion of subjects with a
family history in the control group was 3.2%, while this
proportion is about 1% in the general population in
China [1]. So, the relationship between family history
and risk of breast cancer may be underestimated in this
case–control study.
In this study, triple negative tumors were observed
among 18.3% of patients, a rate comparable to our previ-
ous study [26] and another Chinese study [28]. A lower
proportion of lymph node involvement was observed in
triple negative tumors in this study, which was also com-
parable to previous studies [26,28,29]. Even with less
lymph node involvement, triple negative breast cancers
still show poor prognosis. Thus, it is important to ex-
plore the risk of this subtype of tumors. In this study, we
found a 3.55-fold increased risk of triple negative breast
cancer in women with a family history, which was simi-
lar to that for non-triple negative breast cancer. Further
cohort studies with large sample size are needed to con-
firm our findings.
Most previous studies are focused on the relationship
between family history and risk of invasive breast can-
cers. However, DCIS cannot be ignored, although DCIS
shows encouraging prognosis [30]. A long-term follow-
up study [30] found that the rate of local recurrence was
high, and 48% of these recurrences were invasive. Previ-
ous studies [21-25] suggest that family history is a risk
factor of DCIS. However, no relationship between family
history and risk of DCIS was observed in Han Chinese
people. With the exception of this racial or ethnic differ-
ence, our results might also be influenced by small sample
size and benign breast disease controls. The relationship
between family history and risk of DCIS should be investi-
gated in Asian populations to confirm our findings.
Several limitations still exist in our study. First, subjects
with benign breast disease were selected as controls, so
the association between family history and breast cancer
risk may have been underestimated. Second, the sample
size of DCIS in our study was relatively small; future
studies with large sample sizes are needed to explore
the relationship between family history and risk of DCIS.
Third, owing to the nature of this case–control study,
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explore these relationships.
Conclusions
In conclusion, our results indicate that a family history
of breast cancer is associated with an increased risk of
triple negative breast cancer with a magnitude of associ-
ation similar to that for non-triple negative breast can-
cer. Furthermore, family history was not significantly
associated with an increased risk of DCIS in our study.
Future cohort studies with large sample size are still
needed to explore these relationships.
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